NCT06092931View on ClinicalTrials.gov

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2023

Conditions
Healthy Participants
Interventions
DRUG

DC-806

Oral tablets

DRUG

Midazolam

Oral syrup

DRUG

Repaglinide

Oral tablets

DRUG

Digoxin

Oral tablets

DRUG

Rosuvastatin

Oral tablets

Trial Locations (1)

84124

ICON Phase 1 Clinic, Salt Lake City

All Listed Sponsors
lead

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY